The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

The man in his 40s, who was not identified, had been on the carnivore diet for 8 months when he started to notice the discoloration on the palms of his hands, his elbows and the soles of his feet, ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

ResMed’s stock has surged but faces potential risks from GLP-1 drugs. Find out why RMD stock remains a Hold as investors ...

(FOX40.COM) — A first-time detection of a specific strain of bird flu (H5N1) has been made in a backyard poultry farm in Yolo ...

Most people know that GLP-1 receptor agonist medications like Ozempic and Wegovy can cause relatively minor side effects like ...

Studied over 36 weeks, in doses from 1.25 mg to 20 mg, patients taking amycretin experienced only "mild to moderate" ...

Oprah Winfrey recently detailed how taking weight loss drugs shifted her longtime mindset about what she described as “thin ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...